ESSA Pharma Inc (NASDAQ:EPIX) — Market Cap & Net Worth
Market Cap & Net Worth: ESSA Pharma Inc (EPIX)
ESSA Pharma Inc (NASDAQ:EPIX) has a market capitalization of $9.52 Million ($9.52 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #27282 globally and #5641 in its home market, demonstrating a 5.34% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ESSA Pharma Inc's stock price $0.20 by its total outstanding shares 47308394 (47.31 Million). Also see ESSA Pharma Inc assets under control for a full breakdown of the balance sheet.
ESSA Pharma Inc Market Cap History: 2015 to 2025
ESSA Pharma Inc's market capitalization history from 2015 to 2025. Data shows change from $4.02 Billion to $9.52 Million (-47.57% CAGR). Also see cash efficiency ratio of ESSA Pharma Inc for how efficiently the company converts equity into cash flow.
Index Memberships
ESSA Pharma Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.00% | #776 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #2514 of 3165 |
Weight: ESSA Pharma Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
ESSA Pharma Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ESSA Pharma Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check ESSA Pharma Inc stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
9548883.21x
ESSA Pharma Inc's market cap is 9548883.21 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $2.07 Billion | $217.00 | -$13.14 Million | 9548883.21x | N/A |
Competitor Companies of EPIX by Market Capitalization
Companies near ESSA Pharma Inc in the global market cap rankings as of September 18, 2026. Review EPIX tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to ESSA Pharma Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
ESSA Pharma Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, ESSA Pharma Inc's market cap moved from $4.02 Billion to $ 9.52 Million, with a yearly change of -47.57%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $9.52 Million | -88.76% |
| 2024 | $84.68 Million | -72.88% |
| 2023 | $312.24 Million | +161.90% |
| 2022 | $119.22 Million | -82.25% |
| 2021 | $671.78 Million | +19.03% |
| 2020 | $564.39 Million | +116.91% |
| 2019 | $260.20 Million | +161.90% |
| 2018 | $99.35 Million | -52.12% |
| 2017 | $207.49 Million | -89.99% |
| 2016 | $2.07 Billion | -48.47% |
| 2015 | $4.02 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of ESSA Pharma Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $9.52 Million USD |
| MoneyControl | $9.52 Million USD |
| MarketWatch | $9.52 Million USD |
| marketcap.company | $9.52 Million USD |
| Reuters | $9.52 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ESSA Pharma Inc
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company was incorporated in 2009 and is headquartered in Vancouver, Canada. As of October 9, 2025, ESSA Pharma Inc. operates as a subsidiary of Alexis Bio, Inc.